Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Cho, Yuri ^a   Lee, Dong Hyeon ^a   Lee, Yun Bin ^a   Lee, Minjong ^a   Yoo, Jeong Ju ^a   Choi, Won Mook ^a   Cho, Young Youn ^a   Paeng, Jin Chul ^b   Kang, Keon Wook ^b   Chung, June Key ^b   Yu, Su Jong ^a   Lee, Jeong Hoon ^a   Yoon, Jung Hwan ^a   Lee, Hyo Suk ^a   Kim, Yoon Jun ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; MITOMYCIN; SORAFENIB;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HEPATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PET SCANNER; PRACTICE GUIDELINE; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SOUTH KOREA; THORAX RADIOGRAPHY; DIAGNOSTIC USE; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84937487555     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105679     Document Type: Article

References (37)

1. Haydon GH, Hayes PC (1996) Screening for hepatocellular carcinoma. Eur J Gastroenterol Hepatol 8: 856-860. (Pubitemid 26319386)
2. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750. (Pubitemid 29114292)
3. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC (1997) Increase in primary liver cancer in the UK, 1979-94. Lancet 350: 1142-1143. (Pubitemid 27454010)
4. Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, et al. (1983) Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years. Cancer 51: 863-877. (Pubitemid 13143165)
5. Yuki K, Hirohashi S, Sakamoto M, Kanai T, Shimosato Y (1990) Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 66: 2174-2179.
6. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699. (Pubitemid 26079803)
7. Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30: 1434-1440.
8. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, et al. (2013) Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses. Radiology.
9. Bruix J, Sherman M, Practice Guidelines Committee AAftSoLD (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236. (Pubitemid 43112690)
10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
11. Katyal S, Oliver JH III, Peterson MS, Ferris JV, Carr BS, et al. (2000) Extrahepatic metastases of hepatocellular carcinoma. Radiology 216: 698-703. (Pubitemid 30660840)
12. Honda H, Onitsuka H, Murakami J, Kaneko K, Murayama S, et al. (1992) Characteristic findings of hepatocellular carcinoma: an evaluation with comparative study of US, CT, and MRI. Gastrointest Radiol 17: 245-249.
13. Choi D, Kim SH, Lim JH, Cho JM, Lee WJ, et al. (2001) Detection of hepatocellular carcinoma: combined T2-weighted and dynamic gadolinium-enhanced MRI versus combined CT during arterial portography and CT hepatic arteriography. J Comput Assist Tomogr 25: 777-785. (Pubitemid 32861704)
14. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr., et al. (1998) Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 133: 510-515; discussion 515-516.
15. European Association For The Study Of The L, European Organisation For R, Treatment Of C (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56: 908-943.
16. Iglehart JK (2006) The new era of medical imaging-progress and pitfalls. N Engl J Med 354: 2822-2828.
17. Lee JD, Yun M, Lee JM, Choi Y, Choi YH, et al. (2004) Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 31: 1621-1630. (Pubitemid 40104608)
18. Yoon KT, Kim JK, Kim do Y, Ahn SH, Lee JD, et al. (2007) Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology 72 Suppl 1: 104-110. (Pubitemid 350256673)
19. Bruix J, Sherman M, American Association for the Study of Liver D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
20. Natsuizaka M, Omura T, Akaike T, Kuwata Y, Yamazaki K, et al. (2005) Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 20: 1781-1787. (Pubitemid 43961087)
21. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, et al. (1996) Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23: 1641-1674.
22. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, et al. (1992) Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 33: 333-339.
23. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, et al. (2003) Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 226: 533-542. (Pubitemid 36313446)
24. Dierckx R, Maes A, Peeters M, Van De Wiele C (2009) FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases. Q J Nucl Med Mol Imaging 53: 336-342.
25. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, et al. (1999) Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 94: 3314-3319.
26. Koneru B, Teperman LW, Manzarbeitia C, Facciuto M, Cho K, et al. (2005) A multicenter evaluation of utility of chest computed tomography and bone scans in liver transplant candidates with stages I and II hepatoma. Ann Surg 241: 622-628. (Pubitemid 40397310)
27. Sugiyama M, Sakahara H, Torizuka T, Kanno T, Nakamura F, et al. (2004) 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 39: 961-968. (Pubitemid 39490173)
28. Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 23: 1409-1415.
29. Kim BK, Kang WJ, Kim JK, Seong J, Park JY, et al. (2011) 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 117: 4779-4787.
30. Lee JH, Park JY, Kim do Y, Ahn SH, Han KH, et al. (2011) Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int 31: 1144-1149.
31. Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, et al. (2009) Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 50: 682-687.
32. Ho CL, Yu SC, Yeung DW (2003) 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 44: 213-221.
33. Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, et al. (2008) Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med 49: 1245-1248.
34. Shiomi S, Nishiguchi S, Ishizu H, Iwata Y, Sasaki N, et al. (2001) Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 96: 1877-1880.
35. Lee SD, Kim SH, Kim YK, Kim C, Kim SK, et al. (2013) (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int 26: 50-60.
36. Kim YK, Lee KW, Cho SY, Han SS, Kim SH, et al. (2010) Usefulness 18FFDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl 16: 767-772.
37. Fartoux L, Balogova S, Nataf V, Kerrou K, Huchet V, et al. (2012) A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. Nucl Med Commun 33: 757-765.